This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

BN83495 in Prostate Cancer (STX64PC)

This study has been completed.
Information provided by:
Ipsen Identifier:
First received: November 11, 2008
Last updated: February 28, 2011
Last verified: February 2011
The purpose of the study is to evaluate the pharmacodynamic profile and safety of BN83495 in patients with prostate cancer with disease progression while on androgen ablative therapy

Condition Intervention Phase
Prostate Cancer Drug: BN83495 (Cohort 1) Drug: BN83495 (Cohort 2) Drug: BN83495 (Cohort 3) Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Dose Escalating Study Evaluating the Pharmacodynamic Profile and Safety of BN83495 in Patients With Prostate Cancer With Evidence of Disease Progression While on Androgen Ablative Therapy

Resource links provided by NLM:

Further study details as provided by Ipsen:

Primary Outcome Measures:
  • Absolute and percentage change in levels of hormones from baseline to D28/29 at 6 timepoints [ Time Frame: 28 days ]

Secondary Outcome Measures:
  • Tolerance (Physical Exam, ECOG Performance Status, Electrocardiogram, biochemistry/haematology, Urinalysis, Adverse Events, Concomitant Medications, disease progression) [ Time Frame: Each visit through day 28/29 ]
  • Pharmacokinetic assessments/Pharmacodynamic assessments [ Time Frame: Pre-determined timepoints from baseline to day 28/29 ]

Enrollment: 17
Study Start Date: January 2009
Study Completion Date: February 2011
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort 1
6 patients have been enrolled, the cohort has been completed.
Drug: BN83495 (Cohort 1)
20 mg daily BN83495 for 28 days
Experimental: Cohort 2
6 patients have been enrolled in cohort 2, the cohort has been completed.
Drug: BN83495 (Cohort 2)
40 mg daily BN83495 for 28 days
Experimental: Cohort 3
5 patients have been enrolled in cohort 3. The cohort was closed after the 5th patient enrolled.
Drug: BN83495 (Cohort 3)
60 mg daily BN83495 for 28 days

Detailed Description:
Evaluate the PD profile of BN83495 after 28 days of daily oral administration in patients with locally advanced or metastatic prostate cancer on androgen ablative therapy and with rising prostatic specific antigen

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmed and locally advanced or metastatic prostate cancer with rising prostate-specific antigen (PSA), while on androgen ablative therapy.
  • Over age 18.
  • Demonstrated PSA "biochemical failure".
  • Adequate bone marrow and hepatic function

Exclusion Criteria:

  • Luteinizing Hormone-Releasing Hormone analogue treatment and treated with more than one additional second line of endocrine therapy
  • Prior treatment with ketoconazole
  • Prior chemotherapy for hormone refractory prostate cancer
  • Pre-existing cardiac failure and/or clinically significant abnormal ECG or Echo
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00790374

United States, Maryland
Johns Hopkins University Medical Center
Baltimore, Maryland, United States, 21231
United States, North Carolina
Duke University Medical Center United States
Durham, North Carolina, United States, 27705
United States, Wisconsin
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States, 53705
Sponsors and Collaborators
Study Director: Eric Chetaille, MD Ipsen
  More Information

Responsible Party: Eric Chetaille MD, Ipsen Identifier: NCT00790374     History of Changes
Other Study ID Numbers: X-52-58064-003
Study First Received: November 11, 2008
Last Updated: February 28, 2011

Keywords provided by Ipsen:
Pharmacodynamic profile and safety of BN83495

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases processed this record on September 21, 2017